# A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C

Source: https://onco.cc/trials/nct05170204/  
OnCo record `nct05170204` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Alectinib, Entrectinib, Durvalumab in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT05170204 by Hoffmann-La Roche, with 68 participants enrolled, started 2022-11-01 and due to reach its primary completion in 2030-06-16. Interventions recorded: Alectinib, Entrectinib, Durvalumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05170204
- Phase: 3
- Setting: A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
- Sponsor: Hoffmann-La Roche
- Enrolled: 68

## Sources

- ClinicalTrials.gov NCT05170204: https://clinicaltrials.gov/study/NCT05170204

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Alectinib](https://onco.cc/drugs/alectinib/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Entrectinib](https://onco.cc/drugs/entrectinib/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct05170204.json